• Demethyleneberberine in NSCLC: c-Myc/HIF-1α Senescence

  2026-09-14

  The reference study identifies Demethyleneberberine (DMB) as an inhibitor of NSCLC growth that combines cell-cycle arrest with a senescence-associated response. Its experimental contribution is the linkage of these phenotypes to reduced c-Myc/HIF-1α signaling, providing a mechanistic framework for interpreting DMB in non-small cell lung cancer (NSCLC) research.

• Oleanolic Acid: Liposome Assay Workflow

  2026-09-14

  Use Oleanolic acid to connect iNOS and COX-2 biology with a rigorous dual-loaded liposome workflow. The reference study’s nanoparticle exclusion chromatography approach helps separate free and encapsulated compounds without relying on formulation-specific pretreatment.

• Canagliflozin Remodels Proximal Tubule Mitochondria

  2026-09-13

  A 2025 study found that canagliflozin improved proximal tubular mitochondrial structure and bioenergetics in male hypertensive–diabetic mice, while females showed a mainly structural response. The work expands interpretation of SGLT2 inhibition beyond glucose lowering and highlights sex as an important variable in renal mitochondrial research.

• GW 4869: Mechanism and Exosome Workflows

  2026-09-12

  GW 4869 hydrochloride hydrate is a cell-permeable, noncompetitive neutral sphingomyelinase inhibitor used to study ceramide signaling and extracellular vesicle release. Its strongest application is mechanistic suppression of nSMase-dependent exosome production, but results require vehicle, viability, lipid, and vesicle controls.

• SW033291: 15-PGDH Inhibitor Workflows

  2026-09-11

  SW033291 enables controlled prostaglandin E2 elevation for enzyme, cell, hematopoietic, and tissue-repair studies. This guide connects practical assay design with the latest preclinical evidence that 15-PGDH inhibition can improve muscle recovery during semaglutide-associated weight loss.

• Bsa I (RNase-free): Practical DNA Workflow

  2026-09-11

  Bsa I (RNase-free) supports sequence-directed DNA cleavage in cloning, DNA manipulation, and other molecular biology research workflows where RNA contamination must be minimized. It is intended for controlled research use only and should not be used for diagnostic, clinical, or medical applications.

• Validated HPLC Analysis of Trelagliptin Succinate

  2026-09-10

  The reference study developed and validated a stability-indicating HPLC method for quantifying trelagliptin succinate and eight process-related impurities in pharmaceutical dosage forms. Its combination of multi-impurity separation, forced-degradation testing, and UHPLC-Orbitrap mass spectrometric characterization provides a practical quality-control framework for SYR-472 succinate research.

• Lamotrigine Assays: Mechanism to Measurement

  2026-09-10

  Lamotrigine is a chemically defined sodium channel blocker for epilepsy and cardiac research. This guide moves beyond mechanism summaries to show how assay context, analytical controls, and metabolism-aware interpretation improve the reliability of Lamotrigine experiments.

• Trichostatin A: HDAC Workflow for Cancer Research

  2026-09-09

  Build reproducible TSA experiments that connect histone acetylation with proliferation, differentiation, and receptor-defined breast cancer phenotypes. This practical workflow combines dose setting, chromatin validation, cell-cycle analysis, and the CHK1-focused findings of a breast cancer study.

• Tofacitinib: Reframing RA Macrophage Assays

  2026-09-09

  Tofacitinib (CP-690550) links JAK-dependent cytokine signaling to macrophage metabolism and phenotype in rheumatoid arthritis models. This article develops an assay-centered framework for distinguishing proximal STAT5 effects from broader immunometabolic repair.

• Demethyleneberberine and Neurodegenerative Disease

  2026-09-08

  The 2022 review proposes Demethyleneberberine (DMB) as a neuroprotective candidate by connecting antioxidant, mitochondrial, and anti-inflammatory activity with NF-κB, MAPK, and AMPK signaling. Its main value is mechanistic integration rather than clinical proof, giving researchers a framework for evaluating DMB in neuroinflammation, oxidative stress, and disease-specific cellular models.

• Roscovitine: Designing Better CDK Assays

  2026-09-08

  Roscovitine (Seliciclib) is more than a CDK inhibitor: it is a useful calibration tool for connecting biochemical potency, reversible cell-cycle phenotypes, and assay design. This guide shows how to interpret its selectivity and apply it rigorously in cancer biology research.

• Ouabain Workflows for Na+/K+-ATPase Assays

  2026-09-07

  Build mechanism-focused Ouabain experiments that connect sodium-pump inhibition with calcium handling, viability, and cardiac physiology. This guide combines a practical Na+/K+-ATPase inhibition assay workflow with assay-design lessons from cancer drug-response research, while separating product specifications from starting recommendations.

• Stable Yeast Expression of Exendin-4: Study Review

  2026-09-07

  Balius et al. developed recombinant expression models for Exendin-4, also known as Exenatide, in Escherichia coli and Saccharomyces cerevisiae. Chromosomally integrated yeast produced immunoreactive Exendin-4 at the expected size, providing an early synthetic-biology foundation for more accessible production while leaving bioactivity, purification, oral delivery, and therapeutic efficacy unresolved.

• Angiotensin 1/2 (1-6): An Assay-Design Guide

  2026-09-05

  Angiotensin 1/2 (1-6) is a defined Asp-Arg-Val-Tyr-Ile-His hexapeptide for resolving renin-angiotensin system biology. This guide goes beyond product description to explain fragment identity, assay controls, and the evidentiary boundaries of cardiovascular, renal, and spike-receptor research.

8146 records 1/544 page Next 12345 下5页 Last page